ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

DCE Makes Changes In Procedure For Occupational Studies

November 21, 1986

NCAB, Panel May Look A Discrepancies, In Study Section Evaluation Of Grant Applications

September 4, 1981

Congress Passes HHS Appropriations, Includes $9 Billion for NIH, $575 Million Delayed Funding

November 15, 1991

In Brief: NCAB Lacked Courage On Some Special Actions, Amos Says; Pick Reviewers On Ability Only, Scientist Asks

July 30, 1982

Shorter Hospital Stay After Robot-Assisted Surgeries

February 27, 2009

Diptheria Toxin Prompts Immune System To Kill Cancer

December 29, 2006